PI3K inhibitors in chronic lymphocytic leukemia: where do we go from here?

Phosphatidylinositol 3-kinase (PI3K) inhibitors are effective in chronic lymphocytic leukemia (CLL). However, the severe toxicity profile associated with the first-generation inhibitors idelalisib and duvelisib, combined with the availability of other more tolerable agents, have limited their use. C...

Descripción completa

Detalles Bibliográficos
Autores principales: Skånland, Sigrid S., Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827175/
https://www.ncbi.nlm.nih.gov/pubmed/35899388
http://dx.doi.org/10.3324/haematol.2022.281266

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827175/
https://www.ncbi.nlm.nih.gov/pubmed/35899388
http://dx.doi.org/10.3324/haematol.2022.281266

Ejemplares similares